PURPOSE: To determine the maximum tolerated dose (MTD) and biologic activity of OPB-31121, an oral inhibitor of STAT3, administered twice daily (BID) to subjects with advanced solid tumors. METHODS: Subjects received escalating doses of OPB-31121 BID for the first 21 days of each 28-day cycle in a standard 3 + 3 design. Dose-limiting toxicities (DLTs), safety, pharmacokinetics, and antitumor activity were assessed. RESULTS: Thirty subjects were treated twice daily with OPB-31121 at 6 dose levels: 50 mg (n = 4); 70 mg (n = 3); 140 mg (n = 3); 200 mg (n = 4); 300 mg (n = 9); 350 mg (n = 7). There were no DLTs observed until 300 mg BID (Grade 3 lactic acidosis). At the next dose level (350 mg BID), two subjects had DLTs (Grade 3 vomiting and Grade 3 diarrhea). Thus, 300 mg BID was declared the MTD. OPB-31121-related adverse events included nausea (80 %), vomiting (73 %), diarrhea (63 %), and fatigue (33 %), all of which were primarily grade 1/2. Pharmacokinetics demonstrated high inter-subject variability with exposures 146- to 4,788-fold lower than target concentrations from tumor-bearing mouse models. No objective responses were observed, and all subjects who completed two cycles of treatment had disease progression at their first assessment. CONCLUSIONS: Twice-daily administration of OPB-31121 was feasible up to doses of 300 mg. The pharmacokinetic profile was unfavorable, and no objective responses were observed.
PURPOSE: To determine the maximum tolerated dose (MTD) and biologic activity of OPB-31121, an oral inhibitor of STAT3, administered twice daily (BID) to subjects with advanced solid tumors. METHODS: Subjects received escalating doses of OPB-31121BID for the first 21 days of each 28-day cycle in a standard 3 + 3 design. Dose-limiting toxicities (DLTs), safety, pharmacokinetics, and antitumor activity were assessed. RESULTS: Thirty subjects were treated twice daily with OPB-31121 at 6 dose levels: 50 mg (n = 4); 70 mg (n = 3); 140 mg (n = 3); 200 mg (n = 4); 300 mg (n = 9); 350 mg (n = 7). There were no DLTs observed until 300 mg BID (Grade 3 lactic acidosis). At the next dose level (350 mg BID), two subjects had DLTs (Grade 3 vomiting and Grade 3 diarrhea). Thus, 300 mg BID was declared the MTD. OPB-31121-related adverse events included nausea (80 %), vomiting (73 %), diarrhea (63 %), and fatigue (33 %), all of which were primarily grade 1/2. Pharmacokinetics demonstrated high inter-subject variability with exposures 146- to 4,788-fold lower than target concentrations from tumor-bearing mouse models. No objective responses were observed, and all subjects who completed two cycles of treatment had disease progression at their first assessment. CONCLUSIONS: Twice-daily administration of OPB-31121 was feasible up to doses of 300 mg. The pharmacokinetic profile was unfavorable, and no objective responses were observed.
Authors: Sarah Walker; Chen Wang; Trent Walradt; Bok Sil Hong; Justin R Tanner; Jonathan L Levinsohn; Gerald Goh; Antonio Subtil; Stuart R Lessin; Warren R Heymann; Eric C Vonderheid; Brett A King; Richard P Lifton; Jaehyuk Choi Journal: Blood Date: 2015-12-23 Impact factor: 22.113
Authors: S I Aqel; E E Kraus; N Jena; V Kumari; M C Granitto; L Mao; M F Farinas; E Y Zhao; G Perottino; W Pei; A E Lovett-Racke; M K Racke; J R Fuchs; C Li; Y Yang Journal: Clin Exp Immunol Date: 2019-01-24 Impact factor: 4.330
Authors: Francisco Lopez-Tapia; Christine Brotherton-Pleiss; Peibin Yue; Heide Murakami; Ana Carolina Costa Araujo; Bruna Reis Dos Santos; Erin Ichinotsubo; Anna Rabkin; Raj Shah; Megan Lantz; Suzie Chen; Marcus A Tius; James Turkson Journal: ACS Med Chem Lett Date: 2018-02-16 Impact factor: 4.345
Authors: Ayman J Oweida; Adam C Mueller; Miles Piper; Dallin Milner; Benjamin Van Court; Shilpa Bhatia; Andy Phan; Thomas Bickett; Kimberly Jordan; Theresa Proia; Richard Schulick; Wells A Messersmith; Marco Del Chiaro; Eric Clambey; Michael J Gough; Jason Williams; Kirk Hansen; Karyn Goodman; Sana D Karam Journal: Cancer Immunol Immunother Date: 2020-10-23 Impact factor: 6.968